Pharmaron Beijing Co., Ltd — Board/Management Information 2025

Apr 27, 2025

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

康兹化成

Pharmaron Beijing Co., Ltd.

康龍化成(北京)新藥技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3759)

(1) RESIGNATION AND CESSATION OF OFFICE OF NON-EXECUTIVE DIRECTOR; AND

(2) PROPOSED BY-ELECTION OF NON-EXECUTIVE DIRECTOR OF THE THIRD SESSION OF THE BOARD

The board (the "Board") of directors (the "Directors") of Pharmaron Beijing Co., Ltd. (康龍化成(北京)新藥技術股份有限公司) (the "Company") hereby announces that, the Board resolved and approved, among others, the proposed by-election of non-executive director of the third session of the Board.

1. RESIGNATION AND CESSATION OF OFFICE OF NON-EXECUTIVE DIRECTOR

The Board hereby announces that Mr. Hu Baifeng ("Mr. Hu") has tendered a voluntary resignation from his position as a non-executive Director of the Company and a member of the strategy committee of the Board (the "Strategy Committee"). Following Mr. Hu's resignation, he has voluntarily agreed to continue to perform his duties as a non-executive Director and a member of the Strategy Committee until the proposed election of the new non-executive Director is resolved by the shareholders of the Company (the "Shareholders") at the upcoming annual general meeting of the Company for the year 2024 (the "2024 AGM").

Mr. Hu has confirmed that he has no disagreement with the Board and there is no matter that need to be brought to the attention of the Shareholders with regard to his resignation. As at the date of this announcement, Mr. Hu does not have any interest in the shares of the Company within the meaning of Part XV of the SFO nor any other matter which needs to be brought to the attention of the Shareholders.

The Board would like to take this opportunity to express its appreciation and gratitude to Mr. Hu for his valuable contribution made to the Company during his term of service.

---

2

2. PROPOSED BY-ELECTION OF NON-EXECUTIVE DIRECTOR OF THE THIRD SESSION OF THE BOARD

On April 25, 2025, the Board reviewed and passed a resolution in relation to nominating Ms. Wan Xuan (“Ms. Wan”) as a candidate to stand for election as a non-executive Director of the third session of the Board. The appointment of Ms. Wan will be effective once it is passed by election by the Shareholders at the 2024 AGM.

Subject to being appointed at the 2024 AGM, Ms. Wan will also serve as a member of the Strategy Committee. The term for Ms. Wan’s appointment as a non-executive Director and as a member of the Strategy Committee shall commence upon the passing of election at the 2024 AGM and shall end on the expiry of the term of the current session of the Board. The Company will enter into service agreement with Ms. Wan upon her appointment at the 2024 AGM.

The biographical details of Ms. Wan are as follows:

Ms. Wan Xuan (萬璇), aged 42. Since June 2022, she has worked for CITIC Goldstone Investment Co., Ltd. as the head of investment division 5 (healthcare and biotechnology industry), director, and member of CITIC Goldstone Investment Co., Ltd. Investment Committee. From 2012 to 2022, she worked for Shanghai Panxin Equity Investment Management Co., Ltd. and Beijing Panmao Investment Management Co., Ltd. (an affiliate of CPE Yuanfeng) as principal. From 2008 to 2012, she worked at the Shanghai Stock Exchange.

Ms. Wan obtained her bachelor’s degree in economics from Zhejiang University (浙江大學) in July 2004. She obtained her master’s degree in law from Peking University (北京大學) in July 2007.

Save as disclosed above, Ms. Wan has not held any directorship in any other listed companies in the past three years, and has not held any positions in the Company or its subsidiaries. Ms. Wan has no relationship with any directors, senior management or substantial shareholders of the Company. As at the date of this announcement, Ms. Wan does not have any interest in the shares of the Company within the meaning of Part XV of the SFO.

Save as disclosed above, as at the date of this announcement, there is no other information relating to the proposed election of Ms. Wan that shall be disclosed pursuant to Rule 13.51(2) (h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The Company is not aware of any other matter which needs to be brought to the attention of the Shareholders.

---

3

GENERAL

The Board considers that the proposed by-election of non-executive director of the third session of the Board is in the interests of the Company and the Shareholders as a whole. A circular containing, among other things, details about the proposed by-election of non-executive director of the third session of the Board will be despatched to the Shareholders as soon as practicable.

By order of the Board
Pharmaron Beijing Co., Ltd.
康龍化成(北京)新藥技術股份有限公司
Dr. Lou Boliang
Chairman

Beijing, the PRC
April 27, 2025

As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Li Jiaqing and Mr. Hu Baifeng as non-executive Directors; Ms. Li Lihua, Mr. Tsang Kwan Hung Benson and Mr. Yu Jian as independent non-executive Directors.